Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paricalcitol - Abbvie

Next Previous
Drug Profile

Paricalcitol - Abbvie

Alternative Names: 19-Nor-1-25-OH2D2; 19-Nor-colecalciferol; Paracalcin; Zemplar; Zemplar Capsules

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Cedars-Sinai Medical Center
  • Class Antineoplastics; Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • Phase II Myelodysplastic syndromes

Most Recent Events

  • 25 Aug 2025 Suspended - Phase-III for Secondary hyperparathyroidism (In children, In infants, In neonates) in Puerto Rico, USA (PO), due to strategic considerations (NCT04064827)
  • 25 Aug 2025 AbbVie suspends a phase III trial in Secondary hyperparathyroidism (In neonates, In infants, In children) in Puerto Rico and USA (PO), due to strategic considerations (NCT04064827)
  • 01 Mar 2022 Paricalcitol is still in phase III trials for Secondary hyperparathyroidism (In children, In infants, In neonates) in Puerto Rico (PO) (NCT04064827)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top